|
Delayed
Australian S.E.
08:27:10 12/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 184.76 AUD | +0.50% |
|
+4.41% | +7.03% |
| 10-09 | CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform | MT |
| 10-08 | Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027 | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CSL LIMITED | Biopharmaceuticals | +0.50% | +4.41% | +7.03% | -11.48% | -36.86% | 61.44B |  | |  |
- Stock Market
- Stocks
- CSL Stock
- Charts CSL Limited
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
